Business description: Exelixis, Inc.

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Number of employees: 1,077

Sales by Activity: Exelixis, Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Discovery, Development & Commercialization of New Medicines for Difficult-To-Treat Cancers

1.43B 1.61B 1.83B 2.17B 2.32B

Geographical breakdown of sales: Exelixis, Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States (U.S.)

1.09B 1.41B 1.65B 1.82B 2.14B

Europe

302M 169M 145M 319M 154M

Japan

43.5M 28.73M 39.49M 27.08M 25.59M

Executive Committee: Exelixis, Inc.

Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Investor Relations Contact - -
General Counsel - 2025-11-06

Composition of the Board of Directors: Exelixis, Inc.

Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Director/Board Member 65 2010-07-21
Director/Board Member 55 2016-09-21
Director/Board Member 71 2018-04-04
Director/Board Member 70 2023-05-30
Director/Board Member 43 2023-05-30
Director/Board Member 67 2023-05-30
Director/Board Member 71 2024-01-04

Shareholders: Exelixis, Inc.

NameStocks%Valuation
BlackRock Advisors LLC
10.82 %
26,798,567 10.82 % 1 860 M $
Farallon Capital Management LLC
5.646 %
13,989,010 5.646 % 971 M $
Farallon Capital Management LLC
5.435 %
13,468,010 5.435 % 935 M $
Renaissance Technologies LLC
5.419 %
13,427,993 5.419 % 932 M $
Vanguard Portfolio Management LLC
4.86 %
12,043,122 4.86 % 836 M $

Company details: Exelixis, Inc.

Exelixis, Inc.

1851 Harbor Bay Parkway

94502, Alameda

+650 837 7000

http://www.exelixis.com
address Exelixis, Inc.(EXEL)

Bio Therapeutic Drugs

Change 5-day change 1-year change 3-year change Capi.($)
+0.17%-2.82%+64.51%+236.67% 17.22B
-1.06%-0.07%+60.76%+68.61% 68.32B
+1.30%+7.41%+14.79%+92.69% 60.26B
+0.39%+0.30%+20.04%+98.33% 55.86B
-0.95%+11.17%+22.21%+110.93% 48.43B
-0.23%+4.07%+25.63%+40.08% 45.34B
-6.40%-9.51%+181.99%+816.79% 41.76B
+1.97%+3.50%+25.78%+50.98% 34.5B
-0.56%-0.48%+85.57%+65.40% 33.8B
+1.05%+9.77%-37.66%+408.42% 26.21B
Average -0.43%+1.03%+46.36%+198.89% 43B
Weighted average by Cap. -0.50%+1.27%+46.11%+175.61%
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Exelixis, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
70.70USD
Average target price
61.57USD
Spread / Average Target
-12.91%
  1. Stock Market
  2. Stocks
  3. EXEL Stock
  4. Company Exelixis, Inc.